2014 Curt Stern Award: A Tryst with Genetics1  by Daly, Mark J.
ASHG AWARDS AND ADDRESSES
2014 Curt Stern Award: A Tryst with Genetics1
Mark J. Daly2,3,4,5,*The future beckons to us. Whither do we go and
what shall be our endeavor? . We have hard work
ahead. There is no resting for any one of us till we
redeem our pledge in full.
—Jawaharlal Nehru (‘‘Tryst with Destiny’’)
I do not know which is the greater honor: the truly unex-
pected honor of being recognized by one’s peers in The
Society, for which I’m deeply grateful to the Awards
Committee, or the indescribable honor that Aarno has
just bestowed upon me with his introduction. At both
I am left very nearly speechless.
By means of offering thanks to the numerous people
without whom I certainly would not be standing before
you, I’ll start by giving a very brief glimpse into the activ-
ities that I’ve been privileged enough to be a participant
in and that have led me to where I am. As a boy, I had
always imagined the greatest vistas of science to be those
of space—and then as the 1970s turned to the 1980s,
microelectronics and computing. Without question, when
I began at theMassachusetts Institute of Technology (MIT),
these were the things that I figured to work on—certainly
not biology, which, to be honest, hardcore MIT students
in my day always considered a bit of a ‘‘softer’’ science.
But, as we know, both the world and our view of it are
constantly changing.
At MIT, I was permanently hooked by the elegantly
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The Ameyoung age when I was fortunate enough to join the
brilliant Eric Lander as a summer student at a time
when he was still learning biology and developing the
foundations of quantitative trait locus and homozygosity
mapping with David Botstein, linkage analysis with
Phil Green, and the math of physical mapping and
sequencing with Mike Waterman. Hanging around the
Whitehead Institute and seeing these seminal ideas and
papers forged could for me be described, to say the least,
as ‘‘formative.’’ And it was also at the Whitehead that
I was to meet the only person who has had a greater influ-
ence on my career development—that person, of course,
is my wife, Mary Pat.
I promise not to bore you with my personal history, and
in order to keep to that, I’ll move swiftly through the next
periods of time. The first segment of my career was dedi-
cated to delivering software and algorithms for every fresh
problem in genome mapping. By the close of the 1990s,
however, I had turned to applying the emergent tools of
genomics to complex human disease in general and to
Crohn disease and colitis in particular. This was really a
transition point for me—although it was the mathematics
and computational aspects of genetics that first drew me
in, it is the mission that we could apply these in the service
of medicine with an ultimate goal of improving human
lives that has become my passion, as it is many of yours.
What a privilege it is that this is what we get to do as our
‘‘job’’ every day.
The inflammatory bowel disease (IBD) work led to many
unanticipated opportunities. The first came through pur-
suing one region of the genome at a time when we had
no genome reference or next-generation sequencing
(NGS) techniques and were still genotyping one SNP or
simple sequence-length polymorphisms at a time (molecu-
lar dark ages to some of the younger of you). Through no
more than looking for patterns while hunting for a first
IBD-associated gene (with John Rioux and Tom Hudson),
we came across some of the early evidence of the linkage-
disequilibrium patterns that would drive the HapMap
project, which would in turn lay the groundwork for the
genome-wide association study (GWAS) era.
The HapMap Project began my long-term partnership
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of amazing statistical genetics colleagues around the world
(including the man I’m sharing the podium with this
morning), but more than this, it was in many ways a
launching point in my career. I developed deep collabora-
tions with international researchers—for whom I owe
thanks not only for scientific mentorship and partnership
but also for education on the responsibilities we take on
when we accept the privilege of being medical genetics
researchers. For this, as well as their amazing science,
I am grateful to many, such as Aravinda, Leena and Aarno,
Gert-Jan (who, along with Eric, also became my thesis pro-
moter at Leiden), Leif, and the many Whitehead Institute
faculty who were exceedingly generous mentors when
there was nothing necessarily ‘‘in it’’ for them. It was also
at this time that I was becoming a mentor, and although
it is impossible to thank them all individually, the partner-
ship with so many collaborators and skilled postdocs and
trainees during this time is clearly most responsible for
my being on this stage today.
Throughout the HapMap Project, we were building
toward the idea of genome-wide association, although we
knew we had to wait for technology and partnership to
make this a reality. Although HapMap was hard work
and gave us a framework, and I take no credit for the tech-
nological advances, it’s really the ushering in of a new era
of collaboration that I’mmost proud to have been a partic-
ipant in. Despite the fact that institute heads and promo-
tion committees sometimes acted as though scientific
credit was a zero-sum game, many looked past this and
banded together in collaborations that, at least as far as
genetics was concerned, were unprecedented in scale and
in productivity.
The early work in IBD led me into ever-expanding
collaborations to this day in the genetics of IBD; they
have been remarkably instructive in moving us rapidly
from the time we considered ‘‘complex’’ to mean perhaps
five or ten genes to now having to wrestle with the numer-
ical realities, functional interpretation, and translational
opportunities of diseases with hundreds of contributing
risk factors. For this I must acknowledge the partnership
of the international IBD genetics community and my pro-
foundly brilliant colleague Ramnik Xavier, with whom
I work on the interpretation and translation of these
findings.
Needing to fill a gap left by the end of HapMap—not to
mention an acute unmet need in general—I’ve spentmuch
of my last 10 years on the genetics of autism and schizo-
phrenia, where we’ve seen really the most stunning prog-
ress, first with bona fide copy-number variations and rare
mutations starting in autism and finally with GWAS in
schizophrenia. I cannot overstate the role that collabora-
tions such as the Psychiatric Genetics Consortium and
the Autism Sequencing Consortium are having in this
area, and the transformation of this field in recent years
into one of optimism as incontrovertible proof has
emerged that these diseases are medical, molecular, and
potentially treatable has been breathtaking.370 The American Journal of Human Genetics 96, 369–371, March 5It has also been gratifying to have been able to help
work out how our 1980s-style analytic thinking could be
reapplied to the modern challenges of NGS processing,
calling, and analyses. Moving from early brainstorming
with Eric and others on the first output of next-generation
sequencers to the Genome Analysis Toolkit to what Konrad
presented this morning and to what is now possible for
clinical genetics has been equally breathtaking. During
these recent years, I have been blessed to work with so
many additional fantastic trainees. I would be remiss not
to say that when I asked for the opportunity to hire faculty,
in my wildest dreams I could not have envisioned that two
colleagues as brilliant and committed as Daniel and Ben
would be willing to join this crazy enterprise. To watch
them and their trainees flourish, and being recently joined
by Aarno, is a gift that keeps on giving every day.
Myself included, we have as a community perhaps over-
used Churchill’s ‘‘end of the beginning’’ quote to describe
finally overcoming the first hurdle of gene identification in
complex disease. I’ve recently come to think that a better
analogy might be the transcendent speech delivered by
Nehru on the eve of Indian independence—where in a sin-
gular celebratory moment, he chose to recognize both the
enormity of the challenges that lay ahead and at the same
time the true privilege it was to be in a position to take
them on. This is really the message of this meeting—
what has been accomplished is remarkable, yet we have
so much more ahead of us if we wish to bring genetics
full circle back to individuals. There are so many encour-
aging signs toward this end—collaborative community
efforts to aggregate data and perform anonymous genetic
‘‘matchmaking’’ and other ways in which we can turn n
of 1 into n of significance. The message of Cynthia and
others this week has been that we cannot wait until abso-
lute certainty to engage individuals and patients and that
they will have a right to their genomes—whether for
sharing, second opinions, or what have you. An instructive
analogymay be drawn to the waymedical imaging data are
handled as we wrestle with how to engage patients while
legitimate uncertainty and differences in interpretation
might exist among experts.
In such a world, however, it is absolutely incumbent on
us that we do a much better job of self-policing. We have
learned over and over the importance of laboratory and
statistical rigor in advancing genetic results to patients
or genetic research findings to molecular biologists and
chemists. In all cases, there is so much riding on our expert
interpretation as geneticists. Now, all of us can interpret the
20th mutation in a fully penetrant Mendelian condition or
understand a univariate p value of 1020 or apply Lander-
Kruglyak linkage thresholds—but we have not yet learned
how to amalgamate all available data to interpret rare vari-
ants in unknown genes, or outside genes entirely, and we
certainly have not established a rigorous framework by
which common or rare DNA variation can be turned into
predictors of complex human diseases and phenotypes.
We have confidence that the clinical genetics community, 2015
here, with their longstanding expertise, and efforts by the
American College of Medical Genetics and Genomics,
NCBI, and numerous others will move us in that direction.
That said, the research community needs to resist the
temptation to be a bit more fast and loose with rare muta-
tions in the case where a good story fits, as it so often does.
At this time, we are also seeing waves of papers claiming
the ability to predict common, often psychiatric, traits
from GWAS data—and an even more disturbing trend
that some of these are being directly marketed to clini-
cians—even while the claims are unvalidated and likely
to be misinterpreted. Now, one could simply say that
scientific process sorts these things out over time—but
whether we embrace, or simply acknowledge the inevita-
bility of, an era where individuals and patients are
informed participants in their genome studies, we unques-
tionably need to be our own harshest critics. False connec-
tions between mutation and disease, and false predictions
of devastating psychiatric conditions, have great power to
damage—and rather than hope everyone does the right
thing or wait for some governmental agency to regulate,
we as a community and society should be proactive in
tackling these issues.
If we’re also serious about genetics as a first step in a
long-term effort to rationalize therapeutic development,
we need to embrace partnerships with industry—real
efforts where partners across academia and industry are
designing and interpreting studies together and sharingThe Ameand releasing results to the fullest extent possible and
where ideas and not simply dollars are changing hands.
Certainly this requires some cultural shifts on our end as
well as in the pharmaceutical industry. Our directors and
promotion committees need to value these activities as
critical to our ultimate mission and not as unimportant
diversions. We also need to think of our training responsi-
bility as not just filling the top universities and research
hospitals but also providing the most skilled workforce to
industry so that the entire workforce from basic discovery
to delivery of new therapies is as expert as possible. We also
need to be equally proud of trainees who commit to this
path.
So, Nehru’s call resonates with me, and I urge anyone I
haven’t put to sleep to think on it in this way. Without
question, we are privileged to share a field that offers the
remarkable opportunity to work at the cutting edge of
science while engaged in an endeavor that has as its goal
nothing short of the betterment of the human condition.
Far more than this award today, it is the privilege of going
to work every day that is the real award I’ve received in my
life—excepting of course the greater and even less deserved
reward I have every day of the five people sitting in front
here. For them, for all our families, and for billions around
the world, it’s on us to deliver on the promise of genetics
and genomics in this generation.
So my deepest thanks again go to The Society for this
honor—and let’s get back to work!rican Journal of Human Genetics 96, 369–371, March 5, 2015 371
